Profusa Cleans Up Balance Sheet and Prepares for Major Clinical Reveal in Paris
The digital health pioneer slashes debt while readying its Lumee Oxygen platform for a global stage presentation.
The last four months proved transformative for Profusa (NASDAQ: PFSA). The company emerged from a whirlwind of activity with a significantly lighter debt load and a clear path toward commercialization. Investors watching the digital health space often look for a pivotal moment where a company shifts from survival mode to execution mode. For Profusa, the third quarter of 2025 appears to mark that transition. The Berkeley-based biosensor developer not only completed its merger with NorthView Acquisition Corporation but also aggressively restructured its financials to support a lofty goal: hitting a potential $250 million in revenue by 2030.
Management wasted no time after closing the merger on July 11, 2025. They immediately went to work on the balance sheet. The numbers tell a story of rapid cleanup. At the end of the previous quarter, net debt stood at a heavy $48 million. By October 31, the company had slashed that figure down to just $14 million. This reduction gives the team distinct breathing room as they navigate the capital-intensive waters of medical device commercialization.
The recapitalization effort involved more than just cutting debt. It required bringing in fresh capital to keep the lights on and the machines running. Profusa raised $7 million through an Equity Line of Credit and secured another $2 million via convertible debt. The company effectively repaid and converted $47 million of debt at the close of the business combination. This maneuver simplified the financial picture immensely.
Fred Knechtel, the CFO of Profusa, emphasized the strategic necessity of these moves, noting:
“To deliver value to shareholders and provide the company with adequate capital to achieve near-term revenue goals and define long-term growth strategies, we transformed the company’s balance sheet by raising capital and reducing outstanding indebtedness.”
Also Read: Profusa Charts Bold Path to $250 Million Revenue by 2030
Building the Foundation for Growth
Financial engineering provides the runway, but operational execution builds the plane. Profusa spent the third quarter turning plans into physical assets. The company completed the build-out of its manufacturing capabilities. This step remains critical. Without a robust manufacturing line, the technology remains a concept rather than a product. Now, the company stays on track to begin product shipments in early 2026. This timeline aligns with their projection to generate between $0.5 million and $2 million in potential revenue for that year.
The company also expanded its reach across the Atlantic. Management secured key distributors for the Lumee Oxygen tissue monitoring platform in Europe. These agreements currently cover approximately 35% of the European population. This footprint offers a significant testing ground for the technology before it achieves deeper market penetration. The leadership team views these developments as the initial steps toward a much larger scaling effort.
Ben Hwang, Ph.D., Profusa’s Chairman and CEO, reflected on the intensity of the recent operational push, stating:
“It was an extremely busy four months for the team, and we are proud of our achievements in such a short period of time.”
Investors often look for confidence in the C-suite, and Hwang projects exactly that. The company set a long-term target that demands attention. They aim to capitalize on the Lumee Oxygen opportunity to potentially reach between $9 and $13 million in revenue by 2027. This growth curve serves as the ramp toward their 2030 vision.
Source: Profusa YouTube
Taking the Science to Paris
While the finance team organized the ledgers, the scientific team prepared for a global spotlight. Innovation in the vascular space relies heavily on peer validation and clinical data. Profusa secured a prime opportunity to showcase its technology at the upcoming Paris Vascular Insights (PVI) 2025 conference. The event, scheduled for December 11-13 in Paris, France, attracts the leading minds in vascular and endovascular surgery.
The selection of Profusa’s abstract for a Late Breaking Clinical Trial Update speaks to the relevance of their work. The presentation focuses on the Lumee Oxygen platform and its application for patients with Peripheral Arterial Disease (PAD). Dr. Peter Schneider, a Professor of Surgery at UCSF, will present the data. The medical community continues to seek better ways to monitor tissue health, and Profusa believes it holds the answer.
Their technology differentiates itself by placing the sensor directly within the body. This approach avoids the pitfalls of external sensors that often struggle with consistency. The Lumee platform provides continuous, real-time measurement of tissue oxygen. It creates a personalized biochemical signature that clinicians can track over time.
Hwang highlighted the disruptive nature of this approach in his comments regarding the upcoming presentation, explaining:
“Our Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within the body, a first-of-its-kind, disruptive biochemistry monitoring platform designed for use both in the clinic and at home.”
The presentation in Paris serves as more than just a scientific update. It acts as a marketing tool for the company’s commercial ambitions. A successful reception from the global vascular community could accelerate adoption rates and validate the technology in the eyes of future partners.
As Profusa moves toward the end of 2025, the narrative shifts from “can they survive” to “how fast can they grow.” The combination of a cleaned-up balance sheet, a secured manufacturing pipeline, and a high-profile clinical showcase positions the company for an interesting start to 2026. The market will now watch to see if execution matches the ambition.
Read Next: Why Nvidia’s Tech Investments Could Transform the Entire AI Innovation Ecosystem
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. WealthyVC and our controlling entity 1000724287 Ontario Ltd., have been compensated USD $318,000 for six months for investor relations by Profusa, Inc. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
